|
|
|
|
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
|
|
ITEM 2.02
|
Results of Operations and Financial Condition
|
ITEM 9.01
|
Financial Statements and Exhibits
|
Exhibit
No.
|
|
Description of Document
|
|
|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
|
||
|
|
|
|
Date: February 8, 2023
|
By:
|
/s/ Eli Kalif
|
|
|
|
|
|
|
|
Name:
|
Eli Kalif
|
|
|
Title:
|
Executive Vice President,
|
|
|
|
Chief Financial Officer
|